Cyclooxygenase-2 polymorphisms and the risk of esophageal adeno- or squamous cell carcinoma

doi:10.3748/wjg.15.3493

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 28

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2697)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-3) series.

Item

Count

PDF

254

HTML

2428

Tables (1-3)

Sum=2697

Jul 28, 2009 (publication date) through Mar 10, 2025

Times Cited of This Article

Times Cited (31)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Articles

World J Gastroenterol. Jul 28, 2009; 15(28): 3493-3497
Published online Jul 28, 2009. doi: 10.3748/wjg.15.3493

Table 1 Characteristics of patients with oesophageal carcinoma and controls n (%)

Characteristics	Patients with oesophageal carcinoma				Controls
Characteristics	Total	Adeno carcinoma	Squamous cell carcinoma	Mixed	Controls
n	252	174 (69.0)	70 (27.8)	8 (3.2)	240
Age (yr; mean ± SD)	64.3 ± 10.8	64.7 ± 11.0	62.7 ± 10.2	69.9 ± 8.0	64.6 ± 10.9
Gender
Female	51 (20.2)	24 (13.8)	26 (37.1)	1 (12.5)	51 (21.2)
Male	201 (79.8)	150 (86.2)	44 (62.9)	7 (87.5)	189 (78.8)

Table 2 Distribution of the COX-2 -1195A→G and -765 G→C genotypes and corresponding ORs in patients with oesophageal adenocarcinoma or squamous cell carcinoma versus controls

Genotype COX-2	Adenocarcinoma		Squamous cell carcinoma		Controls n (%)
Genotype COX-2	n(%)	OR (95% CI)	n(%)	OR (95% CI)	Controls n (%)
-1195A→G
-1195A/-1195A	100 (58)	Reference	39 (56)	Reference	154 (64)
-1195G/-1195A	59 (34)	1.13 (0.75-1.73)	26 (37)	1.28 (0.73-2.26)	80 (33)
-1195G/-1195G	15 (9)	3.85 (1.45-10.3)	5 (7)	3.29 (0.95-11.4)	6 (3)
Total	174		70		240
-765 G→C¹
-765G/-765G	112 (69)	Reference	41 (69)	Reference	157 (66)
-765G/-765C	46 (28)	0.88 (0.57-1.37)	16 (27)	0.84 (0.44-1.60)	73 (31)
-765C/-765C	5 (3)	1.17 (0.35-3.92)	2 (3)	1.28 (0.25-6.56)	6 (3)
Total	163		59		236

¹In both the cases and control group, there are some missing data because of unsuccessful PCR; OR: Odds ratio; CI: Confidence interval.

Table 3 COX-2 haplotype distribution and corresponding ORs in patients with oesophageal adenocarcinoma or squamous cell carcinoma carcinoma versus controls

Haplotype COX-2	Adenocarcinoma		Squamous cell carcinoma		Controls n = 236 (%)
Haplotype COX-2	n= 163 (%)	OR (95% CI)	n= 59 (%)	OR (95% CI)	Controls n = 236 (%)
AG/AG	59 (36.2)	Reference	18 (30.5)	Reference	94 (39.8)
AG/AC	29 (17.8)	0.87 (0.50-1.52)	12 (20.3)	1.18 (0.53-2.64)	53 (22.4)
AC/AC	5 (3.1)	1.33 (0.39-4.55)	2 (3.4)	1.74 (0.33-9.32)	6 (2.5)
GC/AC	0 (0)	-	0 (0)	-	0 (0)
GG/AC	17 (10.4)	1.29 (0.63-2.64)	4 (6.8)	0.99 (0.31-3.24)	21 (8.9)
GG/AG	40 (24.5)	1.14 (0.68-1.91)	19 (32.2)	1.77 (0.86-3.66)	56 (23.7)
GG/GG	13 (8.0)	3.45 (1.24-9.58)	4 (6.8)	3.48 (0.89-13.6)	6 (2.5)

Citation: Kristinsson JO, Westerveld PV, Morsche RHT, Roelofs HM, Wobbes T, Witteman BJ, Tan AC, Oijen MGV, Jansen JB, Peters WH. Cyclooxygenase-2 polymorphisms and the risk of esophageal adeno- or squamous cell carcinoma. World J Gastroenterol 2009; 15(28): 3493-3497
URL: https://www.wjgnet.com/1007-9327/full/v15/i28/3493.htm
DOI: https://dx.doi.org/10.3748/wjg.15.3493